{
    "BIDSVersion": "1.6.0",
    "License": "CC0",
    "Name": "Positron emission tomography (PET) quantification in rats of cyclooxygenase-2 (COX-2), a potential biomarker of neuroinflammation",
    "Authors": [
        "Martin Norgaard"
    ],
    "Acknowledgements": "NA",
    "HowToAcknowledge": "Martin Norgaard",
    "Funding": [
        "ZIA-MH002852 (RBI)/NIH/Intramural NIH HHS/United States",
        "ZIA-MH002793 (RBI)/ImNIH/Intramural NIH HHS/United States",
        "NCT03912428 (RBI)/ImNIH/Intramural NIH HHS/United States",
        "NCT04396873 (RBI)/ImNIH/Intramural NIH HHS/United States"
    ],
    "DatasetDOI": "doi:10.18112/openneuro.ds004650.v1.0.2",
    "ReferencesAndLinks": [
        "Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, Singh P, Cortes MY, Henry K, Tye GL, Frankland MP, Montero Santamaria JA, Liow JS, Zoghbi SS, Fujita M, Pike VW, Innis RB. First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3143-3151. doi: 10.1007/s00259-020-04855-2. Epub 2020 May 12. PMID: 32399622; PMCID: PMC8261645.",
        "PET Imaging of the Dopamine Transporter with 18F-FECNT: A Polar Radiometabolite Confounds Brain Radioligand Measurements Sami S. Zoghbi, H. Umesha Shetty, Masanori Ichise, Masahiro Fujita, Maao Imaizumi, Jeih-San Liow, Jay Shah, John L. Musachio, Victor W. Pike, Robert B. Innis Journal of Nuclear Medicine Mar 2006, 47 (3) 520-527;"
    ],
    "EthicsApprovals": [
        "Animal studies adhered strictly to the National Institute of Mental Health Animal Care and Use Committee guidelines and conformed to the Institute of Medicineâ€™s recommendations for laboratory animal care standards. The human component received approval from the National Institutes of Health (NIH) Combined Neurosciences Institutional Review Board (protocol numbers: 19-M-0079 and 20-M-0082; ClinicalTrials.gov identifiers: NCT03912428 and NCT04396873)."
    ]
}